Renalytix plc
("Renalytix" or the "Company")
Appointment of Joint Corporate Broker
LONDON and NEW YORK, 21 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Oberon Capital (a trading name of Oberon Investments Limited) as Joint Corporate Broker with immediate effect.
For further information, please contact:
|
Renalytix plc |
|
|
James McCullough, CEO |
Via Walbrook PR |
|
Stifel (Nominated Adviser and Joint Broker) |
Tel: 020 7710 7600 |
|
Nicholas Moore / Nick Harland / Ben Good |
|
|
Oberon Capital (Joint Broker) |
Tel: 020 3179 5300 |
|
Mike Seabrook / Nick Lovering |
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
Gary Clarence / Shalin Bhamra |
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Alice Woodings / Charlotte Edgar |
Mob: 07407 804 654 / 07884 664 686 |
|
CapComm Partners |
|
|
Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.